Market Update: Australian Central Bank Lowers The Cash Rate. What Factors Can Support Growth?

As the market players are aware, Australian Central Bank has decided to lower the cash rate by 25 bps (or basis points) and, as a result of this, the rate stood at 0.75%. In the media release dated October 1, 2019, it was added that the Australian economy was expanded by 1.4% over the year to June quarter and that was weaker than anticipated. In the release, it was stated that low level of interest rates, spending on infrastructure, recent tax cuts, signs of stabilisation in some established housing markets as well as the brighter outlook with respect to the resources sector might support the growth.

As we know, the trade war between the US and China is one of the biggest threat to the growth of the global economy. The war can weigh over the key financial numbers of the global companies and can also disrupt their primary business activities. It can be assumed that performance of the Australian economy gets affected by health of the global economy. If the Australian economy’s performance is impacted, the affect can also be felt on Australian equities. In the event of slowdown, generally, the market players tend to avoid deployments towards equities, and they prefer deploying towards safer asset classes.

We would now have a look at how markets in Australia have performed on October 2, 2019. S&P/ASX200 index closed the day in red as there was a decline of 102.9 points or 1.5% on an intraday basis. On October 2, 2019, All Ordinaries encountered a fall of 1.5% or 99.7 points to end the session at 6753.3. Let us now have a look at the performance of individual stocks on Australian Securities Exchange. Mayne Pharma Group Limited (ASX: MYX) and CLINUVEL PHARMACEUTICALS LIMITED (ASX: CUV) closed the day in green as the share price of these stocks encountered an increase of 18.868% and 3.308%, respectively. On the other hand, HUB24 Limited (ASX: HUB) and Galaxy Resources Limited (ASX: GXY) encountered a fall of 7.09% and 5.116%, respectively.

We have provided some important information on the stocks which could be beneficial for the readers. Recently, we have covered Pacifico Minerals Limited (ASX: PMY) and we advise the investors to have a quick look at it. In order to view, click here.

A Recent Update By CLINUVEL PHARMACEUTICALS LIMITED

CLINUVEL PHARMACEUTICALS LIMITED (ASX: CUV) came forward and made an announcement via a press release that US Food and Drug Administration (or FDA) has notified the company that Prescription Drug User Fee Act (or PDUFA) goal date for review of submission of SCENESSE® (afamelanotide 16mg) scientific dossier had been miscommunicated by agency and now has been confirmed for October 8, 2019 instead of earlier reported October 6. The release also contained comments of the company’s Chief Scientific Officer named Dr Dennis Wright and he stated that the team continues to engage with FDA at this late stage to address the final questions as well as clarifications on dossier.

MYX Daily Technical Chart (Source: Thomson Reuters)


Disclaimer

This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.

Join Our Discussion

Start discussion with value Investors for ASX Stock Market Investment and Opinion.


6 Cannabis Stocks under Investor’s Limelight…

Cannabis companies that sell both medicinal weed and recreational pot. Marijuana stocks to look at. Marijuana mergers and acquisitions. Dispensary data analytics. Upcoming marijuana IPO’s Those phrases have become increasingly common as marijuana legalization spreads.

Global spending on legal cannabis is expected to grow 230% to $32 billion in 2020 as compared to $9.5 in 2017, according to Arcview Market Research and BDS Analytics. As of June 29, 2018 the United States Marijuana Index, despite a lot of uncertainty around regulations, has over the past 1 year gained 71.49%, as compared to about 12% gain seen by the S&P 500.

Click here for your FREE Report